NCT06823258View on ClinicalTrials.gov

Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
NSCLC (advanced Non-small Cell Lung Cancer)
Interventions
DRUG

HS-10365

HS-10365 administered orally once at D1

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY